Axogen/$AXGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Ticker
$AXGN
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
452
ISIN
US05463X1063
Website
Axogen Metrics
BasicAdvanced
$423M
-
-$0.16
1.19
-
Price and volume
Market cap
$423M
Beta
1.19
52-week high
$21.00
52-week low
$6.59
Average daily volume
720K
Financial strength
Current ratio
4.28
Quick ratio
2.224
Long term debt to equity
65.405
Total debt to equity
67.386
Interest coverage (TTM)
-0.05%
Profitability
EBITDA (TTM)
6.559
Gross margin (TTM)
74.18%
Net profit margin (TTM)
-3.68%
Operating margin (TTM)
-0.20%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-0.13%
Return on equity (TTM)
-7.22%
Valuation
Price to revenue (TTM)
2.137
Price to book
4.01
Price to tangible book (TTM)
4.25
Price to free cash flow (TTM)
-1,872.984
Free cash flow yield (TTM)
-0.05%
Free cash flow per share (TTM)
-0.50%
Growth
Revenue change (TTM)
18.81%
Earnings per share change (TTM)
-67.62%
3-year revenue growth (CAGR)
15.17%
10-year revenue growth (CAGR)
26.44%
3-year earnings per share growth (CAGR)
-40.67%
10-year earnings per share growth (CAGR)
-15.83%
What the Analysts think about Axogen
Analyst ratings (Buy, Hold, Sell) for Axogen stock.
Bulls say / Bears say
Axogen reported a 15.1% increase in Q4 2024 revenue to approximately $49.4 million, indicating strong growth momentum. (stocktitan.net)
The FDA accepted Axogen's Biologics License Application for Avance Nerve Graft, with a PDUFA date set for September 5, 2025, potentially expanding their market reach. (stocktitan.net)
Analysts have raised Axogen's price target to $14, citing strong growth prospects and positive outlooks. (markets.businessinsider.com)
Millennium Management LLC reduced its stake in Axogen by 48.2%, selling 634,391 shares, which may indicate reduced confidence from institutional investors. (marketbeat.com)
ArrowMark Colorado Holdings LLC decreased its holdings in Axogen by 47.42%, selling 2,426,453 shares, potentially signaling concerns about the company's future performance. (gurufocus.com)
Axogen's Q1 2025 earnings reported a loss of $0.02 per share, missing the Zacks Consensus Estimate of a $0.01 loss, which could raise concerns about profitability. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Axogen Financial Performance
Revenues and expenses
Axogen Earnings Performance
Company profitability
Axogen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axogen stock?
Axogen (AXGN) has a market cap of $423M as of June 20, 2025.
What is the P/E ratio for Axogen stock?
The price to earnings (P/E) ratio for Axogen (AXGN) stock is 0 as of June 20, 2025.
Does Axogen stock pay dividends?
No, Axogen (AXGN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Axogen dividend payment date?
Axogen (AXGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Axogen?
Axogen (AXGN) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.